Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

A Study to Evaluate the Performance, Usability, and Contrived Result Interpretation of iStatis Gonorrhea Antigen Test

30 juin 2026 mis à jour par: bioLytical Laboratories

A Study to Evaluate the Performance, Usability, and Contrived Result Interpretation of iStatis Gonorrhea Antigen Test by Trained Personnel at Near-Patient or Point-of-Care Settings

The objective of this study is to evaluate the performance, usability, and contrived result interpretation of iStatis Gonorrhea Antigen Test (iStatis Gonorrhea Test) in the intended near-patient or point-of-care setting by trained personnel.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Intervention / Traitement

Description détaillée

The study is designed to evaluate iStatis Gonorrhea Test performance when used by trained personnel as follows:

  1. A method comparison will be performed to determine the diagnostic sensitivity and specificity of the iStatis Gonorrhea Test compared to a reference test that is an approved, current on-market Gonorrhea/Chlamydia combo assay, Cobas CT/NG.
  2. To evaluate the usability of iStatis Gonorrhea Test by means of assessing user experience via a questionnaire in combination with the success in performing the test. A minimum of 15 intended users to participate in the usability evaluation.
  3. To evaluate and document whether intended users (trained personnel), a minimum of 15 intended users across a minimum of three (3) sites, can successfully interpret contrived iStatis Gonorrhea Test results that include - strong positive, weak positive, negative and a range of invalid results.

Type d'étude

Interventionnel

Inscription (Estimé)

650

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

  • Afrique du Sud
    • Gauteng
      • Johannesburg, Gauteng, Afrique du Sud, 2193
        • Recrutement
        • Epicentre Health Research (Johannesburg)
        • Contact:
    • KwaZulu-Natal
      • Durban, KwaZulu-Natal, Afrique du Sud, 3650
        • Recrutement
        • Epicentre Health Research
        • Contact:
    • Western Cape
      • Cape Town, Western Cape, Afrique du Sud, 7925
        • Recrutement
        • Epicentre Health Research (Cape Town)
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Enfant
  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Oui

La description

Inclusion Criteria

  • Age > 16 years
  • Subject (or legally authorized representative) is willing to provide written informed consent before any study procedures
  • Female gender
  • Subject is able and willing to provide vaginal swab specimen for study procedures (3-4 swabs)
  • Subject can complete the required testing on the allocated testing day
  • Subject can speak, read, and write English
  • Subject's demographic information, risk factors, and symptoms are available and can be recorded on case report forms
  • Subject agrees to comply with study procedures and sample collection for both the investigational device and the reference method
  • Subject is willing to participate in the study site's standard-of-care Gonorrhea counselling and testing program and receive standard-of-care test results, as required and applicable

  • Subject is indicated for sexually transmitted infection testing for one or more of the following reasons:

    • At risk of Gonorrhea, such as recent unprotected intercourse, multiple or new partners within < 60 days, known exposure to an infected partner, or prior STI history
    • Having signs and/or symptoms suggestive of Gonorrhea (e.g., urethral, vaginal, rectal, or pharyngeal discharge; dysuria; pelvic or lower-abdominal pain; sore throat; or rectal discomfort)
    • Undergoing routine or opportunistic STI screening, including family-planning, antenatal, or sexual-health clinic visits
    • Undergoing re-testing (test-of-cure) > 7 days after completion of Gonorrhea treatment and clinically stable
    • Undergoing co-testing for other STIs where Gonorrhea testing is part of a broader diagnostic panel

Exclusion Criteria

  • Subject 15 years of age or younger
  • Male gender
  • Female currently menstruating
  • Subject is unable or unwilling to provide informed consent
  • Subject is medically unstable or has psychiatric condition(s) that pose a risk or prevent study compliance
  • Subject is unable to provide paired samples for reference testing
  • Subject requires urgent antimicrobial treatment before specimen collection
  • Subject received systemic or topical antibiotics active against Gonorrhea within the previous 7 days
  • Subject used topical intravaginal or rectal antiseptics within 48 hours prior to study sampling
  • Previously enrolled for the same infection episode
  • Anatomical or clinical contraindication to study sampling (e.g., severe cervical pathology)
  • Recent urogenital procedure (e.g., cystoscopy, lavage) < 72 hours before study sampling
  • Subject belongs to a protected group excluded by local ethics (e.g., incarcerated persons), unless explicitly approved by the EC/IRB
  • Any condition that, in the opinion of trained personnel or study staff, would make the participant unsuitable or unsafe for enrolment, interfere with completion of assessments, consent, or questionnaires, or bias study outcomes
  • Subject is participating in another interventional clinical study within 30 days that could interfere with study results

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Dépistage
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: iStatis Gonorrhea Test Performance (Operator-collected swabs)
Operator-collected vaginal swabs will be tested on the iStatis Gonorrhea Test
Dispositif: iStatis Gonorrhea Antigen Test
Vaginal swabs are tested on the iStatis Gonorrhea Antigen Test
Expérimental: iStatis Gonorrhea Test Performance (Self-collected swabs)
Self-collected vaginal swabs will be tested on the iStatis Gonorrhea Test. Participants assigned to the self-collection arm of the study will complete the self-collection Usability Questionnaire
Dispositif: iStatis Gonorrhea Antigen Test
Vaginal swabs are tested on the iStatis Gonorrhea Antigen Test
Aucune intervention: Reference Test to evaluate iStatis Performance
Vaginal swabs collected for reference testing will be tested using the Cobas CT/NG reference assay to determine the gonorrhea infection status of participants.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Performance Evaluation
Délai: 3 months
The performance between iStatis Gonorrhea Test and the reference test result for vaginal swabs (operator-collected and self-collected) will be calculated for all sites combined. Diagnostic sensitivity and specificity values and 95% CIs will be calculated for all subjects combined. The percentage of invalids (tests that fail to produce a control dot with accurate use) will be identified and reported.
3 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
iStatis Gonorrhea Test usability evaluation
Délai: 3 months
Overall test usability and self collection usability will be determined via a questionnaire completed by trained personnel who used the device during testing and study participants that performed sample self-collection respectively. The usability questionnaire will use a scale of one (1) to 5 (1 - very difficult/very unlikely to 5 - very easy/very likely), with a rating of 3 being satisfactory.
3 months
iStatis Gonorrhea Test contrived result interpretation evaluation
Délai: 3 months
Trained operators will evaluate a panel of contrived (mock) iStatis devices. These devices are designed to represent a comprehensive range of test outcomes, including strong positives, weak positives, negatives and invalid results. Operators will interpret the results of the mock devices and record their interpretations which will be compared to the correct interpretation of the device.
3 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

bioLytical Laboratories

Collaborateurs

Epicentre

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

26 novembre 2025

Achèvement primaire (Estimé)

1 septembre 2026

Achèvement de l'étude (Estimé)

1 janvier 2027

Dates d'inscription aux études

Première soumission

21 avril 2026

Première soumission répondant aux critères de contrôle qualité

29 avril 2026

Première publication (Réel)

6 mai 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

2 juillet 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

30 juin 2026

Dernière vérification

1 avril 2026

Plus d'information

Termes liés à cette étude

Mots clés

Autres numéros d'identification d'étude

  • CLS-009A

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner